India's 'Mounjaro brides': Weight-loss injections become part of pre-wedding preparation

With wedding season in full swing, Indian health clinics are rolling out specialized weight-loss packages that include popular drugs such as Mounjaro and Wegovy. This emerging trend underscores the immense societal pressure to achieve a perfect look in a short span of time.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/6JtLMfi
via IFTTT

Read More

Indian pharma sector faces supply risk amid West Asia conflict despite duty waiver

India's pharmaceutical industry faces ongoing concerns about securing essential petrochemical supplies due to the West Asia conflict. While a customs duty waiver offers some cost relief, industry experts highlight supply chain disruptions and timely movement as the primary challenges. The government's intervention aims to stabilize supply and lower input costs for critical sectors.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/rDa190b
via IFTTT

Read More

Emcure cuts semaglutide injection price by average 47%

The starting dose price is cut by 55% to Rs 3,999 per month (four weekly doses). The innovator semaglutide is available in a once-weekly pen device in five strengths of 0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg and a maintenance dose of 2.4 mg with the highest dose priced at Rs 8,999 for a month’s supply.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/VXiEGxC
via IFTTT

Read More

Emcure slashes prices of weight management drug Poviztra by up to 55%

Emcure Pharmaceuticals is making its weight management drug Poviztra more accessible. The price of the semaglutide injection will be cut by up to 55 percent. This change begins on April 3, 2026. The aim is to help more people manage obesity. This move supports Emcure's commitment to better health outcomes.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/BQmNeiH
via IFTTT

Read More

Lilly's weight-loss pill wins US approval, sets up next battle with rival Novo Nordisk

The US FDA has approved Eli Lilly's new weight-loss pill, Foundayo. This marks a significant step in the ongoing competition with rival Novo Nordisk in the GLP-1 medicine market. Foundayo is an oral medication offering a new option for weight management. Lilly plans to launch the pill soon, with further global approvals expected this year.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/VD9kGBq
via IFTTT

Read More

Govt cracks down on GLP-1 drugs: Safety first amid weight-loss hype

India's government has released strict rules for GLP-1 drugs, used for diabetes and obesity. These powerful medications are now prescription-only, requiring specialist doctors. Unsupervised sales are banned. Inspections are increasing, with penalties for rule-breakers. Patients must use these drugs only under medical care to avoid side effects. This move ensures safe use and protects public health.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/tRfbqPg
via IFTTT

Read More

'Allocate key chemicals to avert drug shortages', says Pharmexcil amid West Asia war

Indian drug makers face a critical shortage of essential raw materials. Pharmexcil has asked the government to divert supplies of propylene, methanol, ammonia, and butane. These are vital for producing solvents and active pharmaceutical ingredients. Low inventories at solvent manufacturers threaten medicine availability. The government is considering quotas to support the pharma sector.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/AkzbDuo
via IFTTT

Read More